Information Provided By: 
Fly News Breaks for November 21, 2019
ABBV, HARP
Nov 21, 2019 | 09:40 EDT
Roth Capital analyst Zegbeh Jallah said she believes Harpoon Therapeutics' (HARP) expanded agreement with AbbVie (ABBV) is both a strong indication of AbbVie's confidence in the platform as well as "a superb strategic move" for Harpoon. The new deal expands the existing October 2017 discovery and collaboration agreement while also establishing a new licensing and option agreement with Harpoon for HPN217, all while providing "an excellent source of additional cash" for Harpoon, Jallah tells investors. She has a Buy rating on Harpoon shares.
News For HARP;ABBV From the Last 2 Days
There are no results for your query HARP;ABBV
